Pathogenesis and Treatment of Leukemia

This book covers a comprehensive update on acute and chronic leukemia. In 54 chapters, authors introduce research progress and clinical trials of acute myeloid leukaemia (AML), acute promyelocytic leukaemia (APL), acute lymphoblastic leukaemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) and chronic myeloid leukemia (CML). The last decade has seen the integration of genetic and clinical information to determine the prognosis and treatment strategies.

This book provides practitioners, researchers and graduate students of Hematology and Hematopathology a comprehensive update on the pathobiology, genomics, classification, diagnosis, monitoring, prognostication and therapy of both acute and chronic leukemias.

Ch 1 Basic haematopoiesis and leukemia stem cells.- Ch 2 Modern classification of acute and chronic leukemias: integrating biology, clinicopathologic features and genomics.- Ch 3 Molecular techniques in the diagnosis and monitoring of acute and chronic leukemias.- Ch 4 Flow cytometric techniques in the diagnosis and monitoring of acute leukemias.- Ch 5 Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia.- Ch 6 Frontline management of acute myeloid leukaemia eligible for intensive chemotherapy.- Ch 7 Frontline management of elderly acute myeloid leukemia ineligible for intensive treatment.- Ch 8 Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia.- Ch 9 Management of relapsed or refractory AML.- Ch 10 The Role of BCL-2 / MCL-1 targeting in Acute Myeloid Leukemia.- Ch 11 Role of IDH1/IDH2 inhibitors in AML.- Ch 12 Next-generation FLT3 inhibitors for the treatment of FLT3-positive AML.- Ch 13 Allogeneic hematopoietic stem cell transplantation for AML.- Ch 14 Maintenance therapy following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.- Ch 15 Immunotherapeutic targeting of AML.- Ch 16 In the pipeline – Emerging therapy for acute myeloid leukaemia.- Ch 17 Frontline management of acute promyelocytic leukemia.- Ch 18 Management of relapsed acute promyelocyticleukemia and the role of hematopoietic stem cell transplantation.- Ch 19 Genomic Landscape of Acute Lymphoblastic Leukaemia (ALL) – Insights to Leukaemogenesis, Prognostications and Treatment.- Ch 20 Management of adolescent and young adults with Acute Lymphoblastic Leukaemia.- Ch 21 Management of older patients with acute lymphoblastic leukemia.- Ch 22 Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia.- Ch 23 Management of Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (Ph-like ALL).- Ch 24 Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia.- Ch 25 Immunotherapy for ALL.- Ch 26 In the Pipeline - Emerging therapy for ALL.- Ch 27 Inherited/genetic predisposition to MDS and AML.- Ch 28 Clonal hematopoiesis and its functional implications in MDS/AML.- Ch 29 Therapy-related MDS/AML and the role of environmental factors.- Ch 30 Prognostic indicators in MDS and CMML.- Ch 31 Treatment algorithm of myelodysplastic syndromes.- Ch 32 Treatment algorithm of CMML and other uncommon MDS/MPN subtypes.- Ch 33 Novel strategies to manage cytopenia in low-risk MDS.- Ch 34 Allogeneic hematopoietic stem cell transplantation for MDS and CMML: when and how?.- Ch 35 In the Pipeline - Emerging therapy for MDS and MDS/MPN.- Ch 36 Molecular landscape and personalized prognostic prediction of MPNs.- Ch 37 Treatment algorithm of polycythemia Vera.- Ch 38 Treatment algorithm of essential thrombocythemia.- Ch 39 Prognostic models for primary and secondary myelofibrosis.- Ch 40 Treatment algorithm for primary and secondary myelofibrosis.- Ch 41 Diagnosis and management of prefibrotic primary myelofibrosis (pre-PMF).- Ch 42 Interferons In myeloproliferative neoplasms.- Ch 43 JAK inhibitors for the management of myeloproliferative neoplasms.- Ch 44 Allogeneic hematopoietic stem cell transplantation for myelofibrosis – when and how?.- Ch 45 Thrombosis and myeloproliferative neoplasms.- Ch 46 Eosinophilic disorders and systemic mastocytosis.- Ch 47 In the Pipeline - Emerging therapy for classical Ph-negative MPNs.- Ch 48 Current guidelines and treatment algorithm of chronic myeloid leukaemia.- Ch 49 Treatment-free remission in chronic myeloid leukemia.- Ch 50 Treatment options in CML resistant or intolerant to second-generation tyrosine kinase inhibitors.- Ch 51 Allogeneic hematopoietic cell transplantation in CML: when and how?.- Ch 52 In the Pipeline - Emerging therapy for CML.

Ch 1 Basic haematopoiesis and leukemia stem cells.- Ch 2 Modern classification of acute and chronic leukemias: integrating biology, clinicopathologic features and genomics.- Ch 3 Molecular techniques in the diagnosis and monitoring of acute and chronic leukemias.- Ch 4 Flow cytometric techniques in the diagnosis and monitoring of acute leukemias.- Ch 5 Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia.- Ch 6 Frontline management of acute myeloid leukaemia eligible for intensive chemotherapy.- Ch 7 Frontline management of elderly acute myeloid leukemia ineligible for intensive treatment.- Ch 8 Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia.- Ch 9 Management of relapsed or refractory AML.- Ch 10 The Role of BCL-2 / MCL-1 targeting in Acute Myeloid Leukemia.- Ch 11 Role of IDH1/IDH2 inhibitors in AML.- Ch 12 Next-generation FLT3 inhibitors for the treatment of FLT3-positive AML.- Ch 13 Allogeneic hematopoietic stem cell transplantation for AML.- Ch 14 Maintenance therapy following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.- Ch 15 Immunotherapeutic targeting of AML.- Ch 16 In the pipeline – Emerging therapy for acute myeloid leukaemia.- Ch 17 Frontline management of acute promyelocytic leukemia.- Ch 18 Management of relapsed acute promyelocyticleukemia and the role of hematopoietic stem cell transplantation.- Ch 19 Genomic Landscape of Acute Lymphoblastic Leukaemia (ALL) – Insights to Leukaemogenesis, Prognostications and Treatment.- Ch 20 Management of adolescent and young adults with Acute Lymphoblastic Leukaemia.- Ch 21 Management of older patients with acute lymphoblastic leukemia.- Ch 22 Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia.- Ch 23 Management of Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (Ph-like ALL).- Ch 24 Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia.- Ch 25 Immunotherapy for ALL.- Ch 26 In the Pipeline - Emerging therapy for ALL.- Ch 27 Inherited/genetic predisposition to MDS and AML.- Ch 28 Clonalhematopoiesis and its functional implications in MDS/AML.- Ch 29 Therapy-related MDS/AML and the role of environmental factors.- Ch 30 Prognostic indicators in MDS and CMML.- Ch 31 Treatment algorithm of myelodysplastic syndromes.- Ch 32 Treatment algorithm of CMML and other uncommon MDS/MPN subtypes.- Ch 33 Novel strategies to manage cytopenia in low-risk MDS.- Ch 34 Allogeneic hematopoietic stem cell transplantation for MDS and CMML: when and how?.- Ch 35 In the Pipeline - Emerging therapy for MDS and MDS/MPN.- Ch 36 Molecular landscape and personalized prognostic prediction of MPNs.- Ch 37 Treatment algorithm of polycythemia Vera.- Ch 38 Treatment algorithm of essential thrombocythemia.- Ch 39 Prognostic models for primary and secondary myelofibrosis.- Ch 40 Treatment algorithm for primary and secondary myelofibrosis.- Ch 41 Diagnosis and management of prefibrotic primary myelofibrosis (pre-PMF).- Ch 42 Interferons In myeloproliferative neoplasms.- Ch 43 JAK inhibitors for the management of myeloproliferative neoplasms.- Ch 44 Allogeneic hematopoietic stem cell transplantation for myelofibrosis – when and how?.- Ch 45 Thrombosis and myeloproliferative neoplasms.- Ch 46 Eosinophilic disorders and systemic mastocytosis.- Ch 47 In the Pipeline - Emerging therapy for classical Ph-negative MPNs.- Ch 48 Current guidelines and treatment algorithm of chronic myeloid leukaemia.- Ch 49 Treatment-free remission in chronic myeloid leukemia.- Ch 50 Treatment options in CML resistant or intolerant to second-generation tyrosine kinase inhibitors.- Ch 51 Allogeneic hematopoietic cell transplantation in CML: when and how?.- Ch 52 In the Pipeline - Emerging therapy for CML.

Professor Yok-Lam Kwong is Chief of the Division of Haematology, Oncology and Bone Marrow Transplantation at the Department of Medicine, University of Hong Kong.